share_log

HC Wainwright & Co. Maintains Buy on Kiora Pharmaceuticals, Raises Price Target to $3.5

Benzinga ·  Nov 6, 2023 06:42

HC Wainwright & Co. analyst Yi Chen maintains Kiora Pharmaceuticals (NASDAQ:KPRX) with a Buy and raises the price target from $2 to $3.5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment